<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680248</url>
  </required_header>
  <id_info>
    <org_study_id>G285</org_study_id>
    <nct_id>NCT03680248</nct_id>
  </id_info>
  <brief_title>Monitoring of Hepatic Fat Metabolism Using Magnetic Resonance Methods</brief_title>
  <official_title>Monitoring of Hepatic Fat Metabolism Using Magnetic Resonance Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first primary research objective of the study is to determine whether high-fat load (150
      g of fat) induces increase in hepatic fat content (HFC) three and six hours after meal in
      insulin-sensitive subjects with normal HFC (&lt;5% of fat) and in non-diabetic subjects with an
      increased HFC (&gt;5% of fat). Furthermore, the other objective of the study is to determine
      whether the response of HFC to a high-fat load is affected by coadministration of glucose or
      fructose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The epidemic of non-alcoholic fatty liver disease (NAFLD) is becoming a major challenge faced
      by health system worldwide. The hepatic fat comes from the major sources - non-esterified
      fatty acids (NEFA) released from adipose tissue, dietary fat and de novo lipogenesis. Fat
      accumulation in the liver then occurs when triglycerides (TG) that are formed are not rapidly
      enough oxidized or secreted from the liver in very low density lipoproteins (VLDL). It can be
      hypothesized that the capacity of the liver to eliminate TG can be overcome after high load
      of dietary fat. High-fat load should induce an immediate accumulation of hepatic fat that
      could be detected using 1H magnetic resonance spectroscopy (1H-MRS). The accumulation of
      liver fat can be also affected by coadministration of simple carbohydrates - glucose and
      fructose. The administration of these carbohydrates can have a pronounced impact on the
      availability of particular sources of hepatic fat.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2016</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>10 non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) and 10 non-obese non-diabetic subjects with increased hepatic fat content (more than 5% of hepatic fat) will undergo series of six experiments - changes of liver fat content will be measured at time 0, 3 and 6 hours after specific dietary interventions</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic fat content</measure>
    <time_frame>Before time 0 hour, 3 hours, 6 hours</time_frame>
    <description>Change in hepatic fat content as determined by proton magnetic resonance spectroscopy (%) between 0 and 6 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TG</measure>
    <time_frame>before 0, 0.5, 1, 2, 2.5, 3, 4, 4.5, 5, and 6 hours</time_frame>
    <description>Plasma triglyceride concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEFA</measure>
    <time_frame>before 0, 0.5, 1, 2, 2.5, 3, 4, 4.5, 5, and 6 hours</time_frame>
    <description>Plasma non-esterified fatty-acid concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>before 0, 0.5, 1, 2, 2.5, 3, 4, 4.5, 5, and 6 hours</time_frame>
    <description>Plasma glucose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>before 0, 0.5, 1, 2, 2.5, 3, 4, 4.5, 5, and 6 hours</time_frame>
    <description>Plasma insulin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>before 0, 0.5, 1, 2, 2.5, 3, 4, 4.5, 5, and 6 hours</time_frame>
    <description>Plasma glucagon concentration</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hepatic Fat Content</condition>
  <arm_group>
    <arm_group_label>Healthy subjects, Fat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steatosis, Fat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects, Fasting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steatosis, Fasting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects, Fat+Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + glucose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steatosis, Fat+Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + glucose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects, Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - glucose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steatosis, Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - glucose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects, Fat+Fructose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + fructose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steatosis, Fat+Fructose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + fructose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects, Fructose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fructose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steatosis, Fructose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fructose administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fat</intervention_name>
    <description>Subjects will consume dairy cream (150 g of fat) at time 0 hours.</description>
    <arm_group_label>Healthy subjects, Fat</arm_group_label>
    <arm_group_label>Steatosis, Fat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fasting</intervention_name>
    <description>Subjects will fast throughout the experiment.</description>
    <arm_group_label>Healthy subjects, Fasting</arm_group_label>
    <arm_group_label>Steatosis, Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fat+Glucose</intervention_name>
    <description>Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of glucose.</description>
    <arm_group_label>Healthy subjects, Fat+Glucose</arm_group_label>
    <arm_group_label>Steatosis, Fat+Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Subjects will drink herbal tea containing 50 g of glucose at times 0, 2 and 4 hours.</description>
    <arm_group_label>Healthy subjects, Glucose</arm_group_label>
    <arm_group_label>Steatosis, Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fat+Fructose</intervention_name>
    <description>Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of fructose.</description>
    <arm_group_label>Healthy subjects, Fat+Fructose</arm_group_label>
    <arm_group_label>Steatosis, Fat+Fructose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fructose</intervention_name>
    <description>Subjects will drink herbal tea containing 50 g of fructose at times 0, 2 and 4 hours.</description>
    <arm_group_label>Healthy subjects, Fructose</arm_group_label>
    <arm_group_label>Steatosis, Fructose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal response to oral glucose tolerance test

          -  normal glycated hemoglobin

          -  normal aspartate aminotransferase (AST)

          -  normal alanine aminotransferase (ALT)

        Exclusion Criteria:

          -  BMI &gt; 30 kg/m2

          -  use of pharmacological agents affecting insulin sensitivity

          -  use of pharmacological agents affecting lipid metabolism

          -  inability to undergo 1H-MRS examination
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milan Hajek, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Clinical and Experimental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine</name>
      <address>
        <city>Prague 4</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Jan Kovar</investigator_full_name>
    <investigator_title>Head of the laboratory</investigator_title>
  </responsible_party>
  <keyword>hepatic fat content</keyword>
  <keyword>dietary fat</keyword>
  <keyword>glucose</keyword>
  <keyword>fructose</keyword>
  <keyword>non-esterified fatty acid</keyword>
  <keyword>triglyceride</keyword>
  <keyword>insulin</keyword>
  <keyword>postprandial period</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03680248/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03680248/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

